BHC — Bausch Health Companies Inc
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
$6.64
+$0.17 (+2.61%)
Bausch Health Companies Inc (BHC) is a drug manufacturers - specialty & generic company listed on NYSE. It is led by Thomas J. Appio, based in 2150 St. Elzéar Blvd. West, Laval, QC, Canada, H7L 4A8, with about 20,300 employees. Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Latest reported BHC revenue for 2025-09-30 was $2.68B. Net income was $181.0M. Revenue was up 6.0% from 2025-06-30 to 2025-09-30. BHC currently screens at market cap $1.78B.
Use this BHC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BHC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BHC SEC filings page. Lician reads the product cache first so this HTML stays unique to Bausch Health Companies Inc even when a live quote feed is slow.
About Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
BHC Key Statistics
Market Cap
$1.78B
Volume
917,398
Previous Close
$6.68
Day Range
$6.46 – $6.74
P/B Ratio
18.78
EPS
-$0.13
Revenue
$9.63B
Net Income
-$72.00M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+9.9%
Profit Margin
-0.7%
Employees
20,300
BHC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $9.63B | $8.76B | $8.12B | $8.43B |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$72.00M | -$611.00M | -$212.00M | -$937.00M |
| EPS (Diluted) | -$0.13 | -$1.62 | -$0.62 | -$2.64 |
Total Assets
$26.52B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$1.18B
Operating Cash Flow
$1.60B
Free Cash Flow
$0.00
Bausch Health Companies Inc Company Information
- CEO & Director
- Thomas J. Appio
- Headquarters
- 2150 St. Elzéar Blvd. West, Laval, QC, Canada, H7L 4A8
- Website
- www.bauschhealth.com
- Phone
- 514 744 6792
- IPO / Founded
- 1994-03-29
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic